Contraceptive counseling during the pandemic: practical guidelines

Key-points:

• The access to reproductive planning and contraception services during the COVID-19 pandemic is fundamental.

• Contraceptive methods should be initiated or maintained for couples who do not wish to get pregnant during the COVID-19 pandemic.

• There is no known relationship between contraceptive methods and potential treatments against COVID-19.

• There are no specific restrictions for any contraceptive methods in women with COVID-19. Eligibility criteria must be respected for choosing the most appropriate contraceptive modality.

• Conditions must be ensured so that the consultation environment does not become a place of risk of contamination of patients and health professionals.

The National Specialty Commission for Contraception of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO) endorses to this document. The content production is based on scientific studies on a thematic proposal and the findings presented contribute to clinical practice.

Publikationsverlauf

Artikel online veröffentlicht:
30. August 2021

• References

• 1 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20 (05) 533-4
• 2 World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. 2020 [cited 2020 Dec 10]. Available from: http://covid19.who.int/
• 3 Surita FGC, Luz AG, Hsu LPR, Carvalho FHC, Brock MF, Nakamura MU. Outpatient care for pregnant and puerperal women during the COVID-19 pandemic. Rev Bras Ginecol Obstet 2020; 42 (09) 588-92
• 4 Bietsch K, Williamson J, Reeves M. Family planning during and after the West African ebola crisis. Stud Fam Plann 2020; 51 (01) 71-86
• 5 Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012; 120 (06) 1291-7
• 6 Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares-Júnior JM. et al. Contraception and reproductive planning during the COVID-19 pandemic. Expert Rev Clin Pharmacol 2020; 13 (06) 615-22
• 7 Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet 2012; 380 (9837): 149-56
• 8 Tang K, Gaoshan J, Ahonsi B, Ali M, Bonet M, Broutet N. et al. Sexual and reproductive health (SRH): a key issue in the emergency response to the coronavirus disease (COVID- 19) outbreak. Reprod Health 2020; 17 (01) 59
• 9 Short M, Bitzer J, Rowlands S. Testing times. Eur J Contracept Reprod Health Care 2020; 25 (03) 167-8
• 10 Le HH, Connolly MP, Bahamondes L, Cecatti JG, Yu J, Hu HX. The burden of unintended pregnancies in Brazil: a social and public health system cost analysis. Int J Womens Health 2014; 6: 663-70
• 11 Viellas EF, Domingues RMSM, Dias MAB, Gama SGN, Theme Filha MM, Costa JV. et al. Assistência pré-natal no Brasil. Cad Saúde Pública 2014; 30 (Suppl. 01) S85-100
• 12 Bellizzi S, Mannava P, Nagai M, Sobel HL. Reasons for discontinuation of contraception among women with a current unintended pregnancy in 36 low and middle-income countries. Contraception 2020; 101 (01) 26-33
• 13 Caruso S, Rapisarda AMC, Minona P. Sexual activity and contraceptive use during social distancing and self-isolation in the COVID-19 pandemic. Eur J Contracept Reprod Health Care 2020; 25 (06) 445-8
• 14 Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M. et al. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet 2020; 395 (10231): 1175-7
• 15 Mmeje OO, Coleman JS, Chang T. Unintended consequences of the COVID-19 pandemic on the sexual and reproductive health of youth. J Adolesc Health 2020; 67 (03) 326-7
• 16 American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril 2014; 101 (03) 633-4
• 17 World Health Organization (WHO). Medical eligibility criteria for contraceptive use. Geneva: WHO; 2015
• 18 Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB. et al. U.S. Medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016; 65 (03) 1-103
• 19 The American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for Obstetrician–Gynecologists, Gynecology [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.acog.org/clinical-information/physician-faqs/covid19-faqs-for-ob-gyns-gynecology
• 20 Madden T, Secura GM, Nease RF, Politi MC, Peipert JF. The role of contraceptive attributes in women's contraceptive decision making. Am J Obstet Gynecol 2015; 213 (01) 46.e1-6
• 21 World Health Organization. Contraception/Family planning and COVID-19 [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.who.int/news-room/q-a-detail/contraception-family-planning-and-covid-19
• 22 Nanda K, Lebetkin E, Steiner MJ, Yacobson I, Dorflinger LJ. Contraception in the Era of COVID-19. Glob Health Sci Pract 2020; 8 (02) 166-8
• 23 United Nations Population Fund. Sexual and reproductive health and rights: modern contraceptives and other medical supply needs, including for COVID-19 prevention, protection and response [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.unfpa.org/sites/default/files/resource-pdf/COVID-19_Preparedness_and_Response_-_UNFPA_Interim_Technical_Briefs_Contraceptices_and_Medical_Supplies_23_March.pdf
• 24 Sorpreso ICE, Soares Júnior JM, Baracat EC. [Sexually vulnerable women: could reversible long-lasting contraception be the solution?]. Rev Bras Ginecol Obstet 2015; 37 (09) 395-6
• 25 Faculty of Sexual and Reproductive Healthcare. FSRH guidance for contraceptive provision after changes to Covid-19 lockdown [Internet]. 2020 [cited 2020 May 30]. Available from: https://www.fsrh.org/documents/fsrh-guidance-contraceptive-provision-changes-covid-lockdown/
• 26 Federação Brasileira das Associações de Ginecologia e Obstetrícia. Comissão Nacional de Anticoncepção. Anticoncepção durante a pandemia por COVID-19 [Internet]. 2020 [cited 2020 Dec 5]. Available from: https://www.febrasgo.org.br/en/covid19/item/1002-anticoncepcao-durante-a-pandemia-por-covid-19
• 27 Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception 2005; 72 (05) 337-41
• 28 United Nations Development Programme, United Nations Population Fund, World Health Organization, World Bank. Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception 1997; 56 (06) 341-52
• 29 Ti AJ, Roe AH, Whitehouse KC, Smith RA, Gaffield ME, Curtis KM. Effectiveness and safety of extending intrauterine device duration: a systematic review. Am J Obstet Gynecol 2020; 223 (01) 24-35.e3
• 30 Bahamondes L, Fernandes A, Bahamondes MV, Juliato CT, Ali M, Monteiro I. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: a chart review of 776 women in Brazil. Contraception 2018; 97 (03) 205-9
• 31 McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017; 216 (06) 586.e1-6
• 32 Prescribing information for Mirena [Internet]. 2020 [cited 2020 Dec 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021225s040lbl.pdf
• 33 Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S. et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 2016; 31 (11) 2491-8
• 34 Thaxton L, Lavelanet A. Systematic review of efficacy with extending contraceptive implant duration. Int J Gynaecol Obstet 2019; 144 (01) 2-8
• 35 Sitruk-Ware R. Hormonal contraception and thrombosis. Fertil Steril 2016; 106 (06) 1289-94
• 36 Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107 (23 Suppl 1): I9-16
• 37 Asociación Española para el Estudio de la Menopausia, Sociedad Española de Ginecología y Obstetricia, Sociedad Española de Trombosis y Hemostasia. Riesgo tromboembólico en la pandemia de COVID-19 y tratamiento hormonal en mujeres perimenopausicas y postmenopausicas [Internet]. 2020 [cited 2020 Dec 6]. p. 1-9. Available from: https://www.covid-19.seth.es/riesgo-tromboembolico-en-la-pandemia-de-covid-19-y-tratamiento-hormonal-en-mujeres-perimenopausicas-y-postmenopausicas/
• 38 Ramírez I, De la Viuda E, Baquedano L, Coronado P, Llaneza P, Mendoza N. et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemos. Maturitas 2020; 137: 57-62
• 39 Collège National des Enseignants de Gynécologie Médicale, L'Unité d'Hémostase Clinique de Cochin. Prévention du risque thromboembolique veineux chez les femmes COVID + non hospitalisées utilisant un traitement hormonal (Contraception, Traitement hormonal de ménopause, Tamoxifène) [Internet]. 2020 [cited 2020 Dec 10]. Available from: http://www.cngof.fr/coronavirus-go-cngof/apercu?path=HEMOSTASE%2B-%2BRISQUE%2BDE%2BMTE%252FHemostase-PreventionMVTECOVIDHormones.pdf&i=36239
• 40 de Bastos M, Stegeman BH, Rosendaal FR, Van Hylckama Vlieg A, Helmerhorst FM, Stijnen T. et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; (03) CD010813
• 41 Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception 2016; 94 (06) 678-700
• 42 Pires ALR, Batista JG, Aldrighi JM, Massaia IFDS, Delgado DM, Ferreira-Filho ES. et al. Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic. Rev Assoc Med Bras (1992) 2020; 66 (Suppl. 02) 22-6